Targeting DKC1-mediated pseudouridylation combined with PARPi induces synthetic lethality in homologous recombination-proficient tumors
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape of breast cancer susceptibility gene ( BRCA ) mutant tumors by exploiting synthetic lethality arising from homologous recombination (HR) deficiency. Yet, a substantial proportion of solid tumors remain HR-proficient and thu...